XML 24 R48.htm IDEA: XBRL DOCUMENT v2.4.1.9
Business Acquisitions (Details) (USD $)
12 Months Ended 0 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Sep. 26, 2014
Aug. 31, 2013
Business acquisitions          
Net cash paid, net of cash on hand of acquired company $ 3,317,000,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired $ 580,000,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired $ 706,000,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired    
Allocation of the fair value          
Goodwill, non-deductible 10,067,000,000us-gaap_Goodwill 9,772,000,000us-gaap_Goodwill      
Amortization period of acquired intangible assets 12 years        
Minimum          
Allocation of the fair value          
Amortization period of acquired intangible assets 2 years        
Maximum          
Allocation of the fair value          
Amortization period of acquired intangible assets 20 years        
CFR Pharmaceuticals SA          
Business acquisitions          
Cash paid for business acquisition       2,900,000,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Net cash paid, net of cash on hand of acquired company       2,800,000,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Assumed debt       570,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Acquisition cost       3,400,000,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Percentage of voting interest acquired       99.90%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Fair value of the non-controlling interest at the acquisition date       3,000,000us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Allocation of the fair value          
Acquired intangible assets, non-deductible 1,800,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
    1,800,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Goodwill, non-deductible       1,590,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Acquired net tangible assets       70,000,000abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsNet
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Deferred income taxes recorded at acquisition       (540,000,000)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Total preliminary allocation of fair value       2,920,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Cash and cash equivalents       94,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Trade accounts receivable       179,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Inventory       177,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Other current assets       51,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Property and equipment       214,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Other long-term assets       138,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Borrowings       570,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Trade accounts payable and other current liabilities       192,000,000abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Other noncurrent liabilities       15,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
Pro forma financial information          
Annualized net sales expected       800,000,000abt_BusinessAcquisitionsProFormaAnnualizedNetSales
/ us-gaap_BusinessAcquisitionAxis
= abt_CfrPharmaceuticalsSaMember
 
CFR Pharmaceuticals SA | Minimum          
Allocation of the fair value          
Amortization period of acquired intangible assets       12 years  
CFR Pharmaceuticals SA | Maximum          
Allocation of the fair value          
Amortization period of acquired intangible assets       16 years  
CFR Pharmaceuticals SA | Average          
Allocation of the fair value          
Amortization period of acquired intangible assets       15 years  
IDEV Technologies          
Business acquisitions          
Cash paid for business acquisition         310,000,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
Percentage of voting interest acquired         100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
Allocation of the fair value          
Goodwill, non-deductible         112,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
Amortization period of acquired intangible assets         11 years
Pro forma financial information          
Non-deductible acquired in-process research and development         170,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
Non-deductible definite-lived intangible assets         66,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
Net deferred tax liabilities         47,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= abt_IDEVTechnologiesMember
OptiMedica          
Business acquisitions          
Cash paid for business acquisition         260,000,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Percentage of voting interest acquired         100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Allocation of the fair value          
Goodwill, non-deductible         130,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Amortization period of acquired intangible assets         18 years
Pro forma financial information          
Additional payments upon completion of certain development, regulatory and sales milestones         150,000,000us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Non-deductible acquired in-process research and development         60,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Non-deductible definite-lived intangible assets         160,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Net deferred tax liabilities         49,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Contingent consideration         70,000,000us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= abt_OptiMedicaMember
Veropharm          
Business acquisitions          
Cash paid for business acquisition 315,000,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Assumed debt 90,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Acquisition cost 5,000,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Percentage of voting interest acquired 98.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Fair value of the non-controlling interest at the acquisition date 410,000,000us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Allocation of the fair value          
Goodwill, non-deductible 60,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Amortization period of acquired intangible assets 16 years        
Trade accounts receivable 45,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Inventory 25,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Other current assets 10,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Property and equipment 185,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Pro forma financial information          
Non-deductible definite-lived intangible assets 120,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Net deferred tax liabilities 35,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= abt_VeropharmMember
       
Topera          
Business acquisitions          
Cash paid for business acquisition 250,000,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Assumed debt 300,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Allocation of the fair value          
Goodwill, non-deductible 190,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Amortization period of acquired intangible assets 16 years        
Pro forma financial information          
Non-deductible acquired in-process research and development 20,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Non-deductible definite-lived intangible assets 325,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Net deferred tax liabilities 120,000,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember
       
Contingent consideration $ 165,000,000us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= abt_ToperaMember